The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving ...

Following a spike in Covid-19 in Southeast Asia, India has also recently seen fresh cases. According to the Covid-19 ...

COVID-19 remains a concern in several regions, with the JN.1 variant, a descendant of the Omicron BA.2.86 lineage, being the ...

Regulators in the US and UK are reviewing data from another vaccine from Novavax. Sanofi’s shot combines the recombinant DNA technology it uses to make flue vaccines with the adjuvants GSK uses ...

The region's early biomed industry was featured in the February 2013 edition of Prairie Business. The number of biotech ...

The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed ... COVID-19 in hospitalised adult patients. DNA testing company 23andMe looks destined to be taken ...

This week, mRNA vaccines are set to face intense scrutiny from critics in Congress. Here's an explainer of how we know they are safe and effective.

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

Somatic hypermutation (SHM) of immunoglobulin variable (V) regions modulates antibody-antigen affinity is initiated by activation-induced cytidine deaminase (AID) on single-stranded DNA (ssDNA).

Jivi is not indicated for use in patients less than 7 years old due to a greater risk for hypersensitivity reactions and/or loss of efficacy. The Food and Drug Administration (FDA) has expanded ...